Lanso

Lansoprazole, the active ingredient in Lanso, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and related acid‑related disorders.

GNH USA supplies Lanso as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is indicated for several gastrointestinal acid‑related conditions, acting by suppressing gastric acid production. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Erosive esophagitis: reduces acid exposure to allow mucosal recovery. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence. - Helicobacter pylori eradication: used as part of combination therapy to increase eradication rates. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion in this rare endocrine disorder.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhoea: loose stools that may improve with continued therapy. - Nausea: feeling of queasiness, usually transient. - Abdominal pain: discomfort in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, difficulty breathing, or rash. - Clostridioides difficile‑associated diarrhoea: persistent watery stools. - Liver enzyme elevation: signs of hepatic dysfunction. - Hypomagnesemia: low magnesium levels causing muscle cramps or arrhythmias. - Stevens‑Johnson syndrome: severe skin blistering. - Interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in patients with severe impairment. - Monitor magnesium levels: prolonged treatment may cause deficiency. - Review concomitant CYP2C19 inhibitors: may increase lansoprazole exposure. - Use caution in hepatic disease: dose adjustment may be required. - Store at room temperature: keep in the original pack, protect from moisture.

Lansoprazole can affect the pharmacokinetics of several drugs; interaction severity varies.

Major Interactions (Avoid): - Ketoconazole: reduced absorption of ketoconazole. - Atazanavir: decreased atazanavir exposure. - Clopidogrel: reduced activation of clopidogrel.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Phenytoin: may lower lansoprazole plasma levels. - Methotrexate: potential increase in methotrexate concentration.